Trial · NCT01710332
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
NCT01710332, Phase 2, Completed, Wills Eye; results first posted 2017-04-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy. Trials, record NCT01710332. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01710332
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
- NCT number
- NCT01710332
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Wills Eye
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- Intravitreal Aflibercept Injection
- First posted
- 2012-10-19
- Last updated
- 2017-06-16
- Results first posted
- 2017-04-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of Intravitreal Aflibercept Injection | 6 months | Safety will be measured by the amount, significance and details of adverse events/reactions to the study drug. |
| Secondary | Change in Vision Based on Letter Score | 6 months | • Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety of Intravitreal Aflibercept Injection | 6 months | adverse events | NUMBER | |
| SECONDARY | Change in Vision Based on Letter Score | 6 months | ETDRS letters | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of Intravitreal Aflibercept Injection | Intravitreal Aflibercept Injection (x4) | 0 | adverse events | ||
| Safety of Intravitreal Aflibercept Injection | Intravitreal Aflibercept Injection (x6) | 0 | adverse events | ||
| Change in Vision Based on Letter Score | Intravitreal Aflibercept Injection (x4) | -0.3 | Standard Deviation 12.4 | ETDRS letters | |
| Change in Vision Based on Letter Score | Intravitreal Aflibercept Injection (x6) | 4.7 | Standard Deviation 13.4 | ETDRS letters |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravitreal Aflibercept Injection (x4) | 6 | |
| Overall Study | STARTED | Intravitreal Aflibercept Injection (x6) | 6 | |
| Overall Study | COMPLETED | Intravitreal Aflibercept Injection (x4) | 6 | |
| Overall Study | COMPLETED | Intravitreal Aflibercept Injection (x6) | 6 | |
| Overall Study | NOT COMPLETED | Intravitreal Aflibercept Injection (x4) | 0 | |
| Overall Study | NOT COMPLETED | Intravitreal Aflibercept Injection (x6) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intravitreal Aflibercept Injection (x4) | ||
| Total, all-cause mortality | Intravitreal Aflibercept Injection (x6) | ||
| Total, other adverse events | Intravitreal Aflibercept Injection (x4) | 0 | 6 |
| Total, other adverse events | Intravitreal Aflibercept Injection (x6) | 0 | 6 |
| Total, serious adverse events | Intravitreal Aflibercept Injection (x4) | 0 | 6 |
| Total, serious adverse events | Intravitreal Aflibercept Injection (x6) | 0 | 6 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Intravitreal Aflibercept Injection (x4) vs Intravitreal Aflibercept Injection (x6): serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01710332
GET https://conductscience.org/api/trials/v1/NCT01710332/registered